Need Help?

Comprehensive Molecular Analysis of Colon Cancer for the Identification and Validation of New Biomarkers

This study aims to identify diagnostic and prognostic biomarkers in colon cancer and to study understand the complex genomic, genetic and epigenetic relationships with a multiomic approach. The study includes tumor and paired normal mucosa of 100 colon cancer patients diagnosed at stage II, untreated and with microsatellite stable tumours. Also 50 normal mucosa samples from healthy donors are included as reference. The samples have been analysed for gene expression with Affymetrix U219 array (available at GEO GSE44076), SNP/CNV with the Affymetrix 6.0 Human SNP array, for DNA methylation with the Illumina 450K array. Small RNAs were sequenced with the Solid technology and 42 of the tumours and paired normal mucosa DNA were whole exome sequenced with Illumina Genome Analyzer.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004826 Illumina HiSeq 2000 84
EGAD00001004827 AB SOLiD System 250
EGAD00010001253 Affymetrix SNP 6.0 245
Publications Citations
Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component.
Br J Cancer 117: 2017 421-431
Colon-specific eQTL analysis to inform on functional SNPs.
Br J Cancer 119: 2018 971-977
Identifying causal models between genetically regulated methylation patterns and gene expression in healthy colon tissue.
Clin Epigenetics 13: 2021 162
Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.
J Pathol 257: 2022 68-81
COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients.
Sci Data 9: 2022 595
Identification of a Twelve-microRNA Signature with Prognostic Value in Stage II Microsatellite Stable Colon Cancer.
Cancers (Basel) 15: 2023 3301